The Supreme Court is reviewing the legality of the Universal Service Fund (UYF), used to fund phone and internet services in ...

Brain atrophy occurs over time regardless of education level. Our findings suggest that attending higher education may enable people to retain greater cognitive ability until a critical threshold of ...

When someone has a stroke, it can accelerate the loss of cognitive ability over the coming years. Stroke survivors who have ...

Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...

Conversations with over a dozen college students across the US revealed fears of developing an over-reliance on AI.

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Researchers at Penn Vet and the University of Padova identified a novel variant connected to progressive retinal atrophy ...

Frederic L.W.V.J. Schaper, MD, PhD, director of Epilepsy Network Mapping at the Center for Brain Circuit Therapeutics at Brigham and Women's Hospital and an instructor of neurology at Harvard Medical ...

Activating a protein called potassium channel Kv2.1 may help improve motor function in SMA, making it a potential SMA ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...